Assessment of the efficacy and safety of lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer in real-life practice in Russia

被引：0
|
作者：
Borodavina, E. [1 ]
Isaev, P. [1 ]
Shurinov, A. [1 ]
Krylov, V. [1 ]
机构：
[1] A Tsyb Med Radiol Res Ctr, Radionuclide Therapy Dept, Obninsk, Russia
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1923P
引用
下载
收藏
页码：S1089 / S1090
页数：2
相关论文
共 50 条
  • [41] Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine-refractory differentiated thyroid cancer
    Martinez-Trufero, Javier
    CANCER MEDICINE, 2022, 11 : 5 - 9
  • [42] Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients
    Fukuda, Naoki
    Toda, Kazuhisa
    Wang, Xiaofei
    Ohmoto, Akihiro
    Hayashi, Naomi
    Urasaki, Tetsuya
    Sato, Yasuyoshi
    Nakano, Kenji
    Ono, Makiko
    Tomomatsu, Junichi
    Mitani, Hiroki
    Takahashi, Shunji
    ENDOCRINE JOURNAL, 2021, 68 (06) : 639 - 647
  • [43] Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial (vol 35, pg 2692, 2017)
    Brose
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 931 - 931
  • [44] Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis
    Shen, Chen-Tian
    Qiu, Zhong-Ling
    Luo, Quan-Yong
    ENDOCRINE-RELATED CANCER, 2014, 21 (02) : 253 - 261
  • [45] Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer
    Kiyota, Naomi
    Schlumberger, Martin
    Muro, Kei
    Ando, Yuichi
    Takahashi, Shunji
    Kawai, Yasukazu
    Wirth, Lori
    Robinson, Bruce
    Sherman, Steven
    Suzuki, Takuya
    Fujino, Katsuki
    Gupta, Anubha
    Hayato, Seiichi
    Tahara, Makoto
    CANCER SCIENCE, 2015, 106 (12) : 1714 - 1721
  • [46] Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
    French, Jena D.
    Haugen, Bryan R.
    Worden, Francis P.
    Bowles, Daniel W.
    Gianoukakis, Andrew G.
    Konda, Bhavana
    Dadu, Ramona
    Sherman, Eric J.
    McCue, Shaylene
    Foster, Nathan R.
    Nikiforov, Yuri E.
    Farias, Ticiana D. J.
    Norman, Paul J.
    Wirth, Lori J.
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3757 - 3767
  • [47] Treatment of radioiodine refractory high-differentiated thyroid cancer with lenvatinib.
    Romanov, Ilya
    Mudunov, Ali
    Isaev, Pavel
    Bychkov, Yury
    Odzharova, Akgul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
    Herranz, Urbano Anido
    CANCER MEDICINE, 2022, 11 : 47 - 53
  • [49] A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients
    Fukuda, Naoki
    Toda, Kazuhisa
    Udagawa, Shohei
    Ohmoto, Akihiro
    Oki, Ryosuke
    Suto, Hirotaka
    Wang, Xiaofei
    Hayashi, Naomi
    Urasaki, Tetsuya
    Sato, Yasuyoshi
    Nakano, Kenji
    Ono, Makiko
    Tomomatsu, Junichi
    Mitani, Hiroki
    Takahashi, Shunji
    ENDOCRINE, 2022, 76 (01) : 70 - 77
  • [50] Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
    Suzuki, Chiaki
    Kiyota, Naomi
    Imamura, Yoshinori
    Goto, Hideaki
    Suto, Hirotaka
    Chayahara, Naoko
    Toyoda, Masanori
    Ito, Yasuhiro
    Miya, Akihiro
    Miyauchi, Akira
    Teshima, Masanori
    Otsuki, Naoki
    Nibu, Ken-ichi
    Minami, Hironobu
    FRONTIERS IN ONCOLOGY, 2021, 11
12345